Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
Latest Information Update: 31 Mar 2023
Price :
$35 *
At a glance
- Drugs Mesothelin CAR T cell therapy Novartis/University of Pennsylvania (Primary)
- Indications Adenocarcinoma; Malignant-mesothelioma; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Peritoneal cancer
- Focus Adverse reactions
- 24 May 2018 New trial record